This week in psychedelic business news: a psilocybin delivery system for brain inflammation, a genetic test to predict your psychedelic-assisted therapy experience, and a potential first treatment for a debilitating form of schizophrenia.
This week in psychedelic business news: cannabis dives in, ketamine delivery, and psilocybin for autism anxiety.
This week in psychedelic business news sees pharmaceutical giant Merck enter the arena, psilocybin research, and more.
This week in psychedelic business news, Canada expands legal distribution for psychedelics, therapeutic DMT stroke treatment, and more.
This week in psychedelic business news: two companies enter the Canadian Stock Exchange, AI comes to psychedelic treatment, and psilocybin comes to Brazil.
This week in psychedelic business news, Field Trip upsizes its bought deal, psilocybin truffles head to Brazil, another company goes public, and more.
This week in psychedelic business news: MindMed acquires a digital health company, Mindest Pharma goes public, new MDMA treatment for PTSD, and more.
This week in Psychedelic business news: MindMed has a new partner, Mydecine closes a funding round, and the world’s first legal psilocybin cultivation facility launches.
This week in psychedelic business news, Super Mario’s magic mushroom gets a new use, Mindset files three patents, Bright Minds goes public, and more.
This week in psychedelic business news, Psyence Group’s psilocybin harvest, NeonMind’s new CEO, and Mydecine sponsors new research.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.